# DAT-2645

Source: https://onco.cc/drugs/dat-2645/  
OnCo record `dat-2645` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DAT-2645 is an experimental small molecule from Danatlas Pharmaceuticals, in phase 2 trials for solid tumours with BRCA1/2 or DNA damage repair defects and BRCA-mutated or HRD-positive ovarian cancer.

## Summary

DAT-2645 is a small molecule (oral tablet) from Danatlas Pharmaceuticals. An oral PARG inhibitor for tumours with BRCA1/2 loss of function or other DNA damage repair defects. Its furthest stage is phase 2, for solid tumours with BRCA1/2 or DNA damage repair defects and BRCA-mutated or HRD-positive ovarian cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 NCT06614751 and phase 2 NCT07652073 both not yet recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DAT-2645
- Modality: Small molecule (oral tablet)
- Mechanism: An oral PARG inhibitor for tumours with BRCA1/2 loss of function or other DNA damage repair defects.

## Sources

- Danatlas Pharmaceuticals: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06614751
- Danatlas Pharmaceuticals: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07652073
- ClinicalTrials.gov: trials of DAT-2645: https://clinicaltrials.gov/search?intr=DAT-2645

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PARG](https://onco.cc/targets/parg/)
- companies: [Danatlas Pharmaceuticals](https://onco.cc/companies/danatlas-pharmaceuticals/)
- trials: [A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway](https://onco.cc/trials/nct06614751/), [A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer](https://onco.cc/trials/nct07652073/)

---
JSON: https://onco.cc/api/v1/entities/dat-2645.json